-
Detailed Analysis Download Full Stock Report Add to Watchlist
Values as of: 2022-05-24
Last Closing Price
USD 44.57Change
-5.35 (-10.72)%Market Cap
N/AVolume
0.24MYahoo Analyst Target
N/AAvg Analyst Target
USD 83.83 (+88.09%)Verdict
Verdict
Values as of: 2022-05-24
Last Closing Price
USD 44.57Change
-5.35 (-10.72)%Market Cap
N/AVolume
0.24MYahoo Analyst Target
N/AAvg Analyst Target
USD 83.83 (+88.09%)Verdict
Verdict
Currency: USD
Country : United States
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
ACWI | iShares Trust - iShares MSCI A.. |
-0.74 (-0.83%) |
USD17.91B | 17.30 | N/A |
CGABL | The Carlyle Group Inc. 4.625% .. |
-0.13 (-0.69%) |
USD16.14B | N/A | N/A |
CNXCV | Concentrix Corporation |
N/A |
USD4.91B | N/A | 12.00 |
BUG | Global X Funds - Global X Cybe.. |
-0.69 (-2.66%) |
USD1.28B | N/A | N/A |
TCRX | Tscan Therapeutics Inc |
+0.03 (+1.05%) |
USD0.82B | N/A | -298.06 |
AGCWW | Altimeter Growth Corp |
N/A |
USD0.74B | N/A | N/A |
ERESW | East Resources Acquisition Com.. |
N/A |
USD0.42B | N/A | N/A |
FREEW | FREEW |
N/A |
USD0.28B | -99,999.99 | N/A |
NFIN | Netfin Acquisition Corp |
N/A |
USD0.26B | N/A | N/A |
HERO | Global X Funds - Global X Vide.. |
-0.34 (-1.50%) |
USD0.26B | N/A | N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|
N/A
Market Performance vs. Industry/Classification (Others) |
Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -31.41% | 42% | F | 40% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -31.41% | 42% | F | 40% | F | ||
Trailing 12 Months | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | N/A | N/A | N/A | N/A | N/A | ||
Risk Adjusted Return | N/A | N/A | N/A | N/A | N/A | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 87%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Ratio vs. Industry/Classification (Others) |
Ratio vs. Market |
||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
Market Value | |||||||
Price / Earning Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price/Book Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price / Cash Flow Ratio | N/A | N/A | N/A | N/A | N/A | ||
EV/EBITDA | N/A | N/A | N/A | N/A | N/A | ||
Management Effectiveness | |||||||
Return on Equity | N/A | N/A | N/A | N/A | N/A | ||
Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | ||
Return on Assets | N/A | N/A | N/A | N/A | N/A | ||
Debt to Equity Ratio | N/A | N/A | N/A | N/A | N/A | ||
Technical Ratios | |||||||
Dividend Yield | N/A | N/A | N/A | N/A | N/A | ||
Short Ratio | N/A | N/A | N/A | N/A | N/A | ||
Short Percent | N/A | N/A | N/A | N/A | N/A | ||
Beta | N/A | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
User Name | Target Rating | Target Horizon (Months) | Target Price | User Analysis | Date | Comment |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
There is nothing we particularly dislike